Post-Marketing Surveillance: The Obligation That Outlasts the Acquisition

← Back to All Insights

FDA approval is not the end of regulatory obligations—it is the beginning of a different set. Post-marketing surveillance commitments, post-approval studies, real-world evidence obligations, and Medical Device Reporting all continue indefinitely. For acquirers, these obligations transfer with the asset and frequently surface as unexpected operating cost in the first year post-close.

Post-marketing obligations are not the same as warranties. They cannot be assigned away. They cannot be insured against. They become the acquirer's responsibility on day one.

Categories of Post-Marketing Obligations

The most common categories: Post-Approval Studies (PAS) required as a condition of approval; Post-Market Surveillance Studies (522 studies) ordered by FDA based on signal detection; Real-World Evidence commitments tied to specific labeling claims; Medical Device Reporting (MDR) of adverse events and device malfunctions; Field Action obligations when issues are identified.

PAS Backlog at FDA

FDA's PAS database includes hundreds of studies in various states of completion. A significant fraction are years behind their original timeline. Sponsors who fall further behind face FDA enforcement actions ranging from labeling changes to withdrawal proceedings. Acquirers regularly inherit PAS backlogs they did not budget.

The 522 Study Surprise

Section 522 of the FDCA authorizes FDA to require post-market surveillance studies on Class II and Class III devices when needed to assess safety. These studies can be ordered years after approval if surveillance data raises concerns. The cost—typically $2-15M—falls on the current manufacturer regardless of when the device was approved.

Real-World Evidence Commitments

Modern FDA approvals increasingly include real-world evidence (RWE) commitments tied to labeling claims. These may involve registry participation, claims database analysis, or prospective observational studies. The infrastructure to deliver RWE is non-trivial—acquirers without existing RWE capability face significant buildout costs.

Diligence Approach

Pull FDA's PAS database for the target's products. Examine the target's MDR submission history relative to industry norms. Request FDA correspondence files showing any 522 study orders or pending discussions. Examine the QMS records for open CAPAs related to surveillance signals. Build the projected obligation cost into the deal financial model—not as a contingency but as a known operating expense.

Post-marketing obligations are predictable, persistent, and inheritable. Acquirers who treat them as exotic edge cases consistently underestimate first-year post-close operating costs. Disciplined diligence quantifies these obligations explicitly and prices them into the deal.